Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the second quarter, Holdings Channel reports. The institutional investor owned 2,313,496 shares of the biopharmaceutical company’s stock after acquiring an additional 36,821 shares during the quarter. Franklin Resources Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,214,585,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in REGN. Brighton Jones LLC grew its position in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the period. IFP Advisors Inc boosted its holdings in Regeneron Pharmaceuticals by 178.3% in the 1st quarter. IFP Advisors Inc now owns 1,024 shares of the biopharmaceutical company’s stock worth $649,000 after buying an additional 656 shares during the last quarter. Crestwood Advisors Group LLC increased its stake in Regeneron Pharmaceuticals by 5.7% during the 1st quarter. Crestwood Advisors Group LLC now owns 467 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 25 shares in the last quarter. Choreo LLC raised its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the first quarter. Choreo LLC now owns 3,746 shares of the biopharmaceutical company’s stock valued at $2,376,000 after acquiring an additional 32 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Up 4.9%

Shares of NASDAQ:REGN opened at $737.00 on Friday. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $611.37 and a 200-day simple moving average of $574.54. The company has a market capitalization of $77.46 billion, a PE ratio of 17.65, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the firm posted $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Analyst Ratings Changes

Several research firms recently commented on REGN. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 price target on the stock. Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the stock an “equal weight” rating in a research report on Thursday. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a report on Monday, August 4th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $776.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.